Blockade of the G-CSF Receptor Is Protective in a Mouse Model of Renal Ischemia-Reperfusion Injury.
Animals
Chemokines
/ metabolism
Complement Activation
/ drug effects
Creatinine
/ blood
Disease Models, Animal
Gene Expression
/ drug effects
Inflammation
/ blood
Kidney
/ drug effects
Kidney Diseases
/ blood
Macrophages
/ drug effects
Male
Mice
Mice, Inbred C57BL
Neutrophils
/ drug effects
Protective Agents
/ pharmacology
Receptors, Granulocyte Colony-Stimulating Factor
/ antagonists & inhibitors
Reperfusion Injury
/ blood
Urea
/ blood
Journal
Journal of immunology (Baltimore, Md. : 1950)
ISSN: 1550-6606
Titre abrégé: J Immunol
Pays: United States
ID NLM: 2985117R
Informations de publication
Date de publication:
01 09 2020
01 09 2020
Historique:
received:
09
04
2020
accepted:
02
07
2020
entrez:
26
8
2020
pubmed:
26
8
2020
medline:
23
3
2021
Statut:
ppublish
Résumé
Ischemia-reperfusion injury (IRI) is a complex inflammatory process that detrimentally affects the function of transplanted organs. Neutrophils are important contributors to the pathogenesis of renal IRI. Signaling by G-CSF, a regulator of neutrophil development, trafficking, and function, plays a key role in several neutrophil-associated inflammatory disease models. In this study, we investigated whether targeting neutrophils with a neutralizing mAb to G-CSFR would reduce inflammation and protect against injury in a mouse model of warm renal IRI. Mice were treated with anti-G-CSFR 24 h prior to 22-min unilateral renal ischemia. Renal function and histology, complement activation, and expression of kidney injury markers, and inflammatory mediators were assessed 24 h after reperfusion. Treatment with anti-G-CSFR protected against renal IRI in a dose-dependent manner, significantly reducing serum creatinine and urea, tubular injury, neutrophil and macrophage infiltration, and complement activation (plasma C5a) and deposition (tissue C9). Renal expression of several proinflammatory genes (CXCL1/KC, CXCL2/MIP-2, MCP-1/CCL2, CXCR2, IL-6, ICAM-1, P-selectin, and C5aR) was suppressed by anti-G-CSFR, as was the level of circulating P-selectin and ICAM-1. Neutrophils in anti-G-CSFR-treated mice displayed lower levels of the chemokine receptor CXCR2, consistent with a reduced ability to traffic to inflammatory sites. Furthermore, whole transcriptome analysis using RNA sequencing showed that gene expression changes in IRI kidneys after anti-G-CSFR treatment were indistinguishable from sham-operated kidneys without IRI. Hence, anti-G-CSFR treatment prevented the development of IRI in the kidneys. Our results suggest G-CSFR blockade as a promising therapeutic approach to attenuate renal IRI.
Identifiants
pubmed: 32839213
pii: jimmunol.2000390
doi: 10.4049/jimmunol.2000390
doi:
Substances chimiques
Chemokines
0
Protective Agents
0
Receptors, Granulocyte Colony-Stimulating Factor
0
Urea
8W8T17847W
Creatinine
AYI8EX34EU
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1433-1440Informations de copyright
Copyright © 2020 by The American Association of Immunologists, Inc.